Home
Storia in 1 fonti
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from a year ago. | Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth. It was an uptick from 2025 when there were six drugmakers that had double-digit increases in each of the four quarters.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
- ·
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from…
- ·
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for…
- ·
Inside agency view: Ogilvy Health on AI’s ‘light speed,’ nano influencers and the rise of Ria
Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics are putting more pressure on the industry. |…
- ·
AbbVie, GSK race up patient reputation leaderboard in the UK
AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards. |…